Navigation Links
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Date:8/19/2007

- Top Line Results Expected to Be Reported in 4Q 2007 -

LA JOLLA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has completed enrollment in its Phase IIb clinical trial of tezampanel for the treatment of acute migraine headache. Tezampanel is an AMPA/kainate (AK) receptor antagonist that offers a non-opioid, non-vascular and non-serotonergic approach to the management of pain and represents a potentially new and promising alternative to current migraine treatments.

The clinical trial is a double-blind, placebo-controlled, multi-center trial that reached its targeted enrollment of 300 patients suffering a single migraine attack, with or without aura. Patients are randomized to one of four arms and receive a 40 mg, 70 mg, or 100 mg single, subcutaneous dose of tezampanel or placebo. The purpose of the trial is to identify a dose, or a range of doses, that could be used in a Phase III development program for tezampanel in acute migraine. The primary efficacy endpoint for the trial is headache pain relief at two hours post-dose. Secondary efficacy endpoints include pain free status at two hours, sustained pain relief and sustained pain free at 24 hours, and headache recurrence and relapse. Additional measures include assessments of functional disability and patient satisfaction, relief of migraine-associated symptoms such as nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound), as well as various assessments that characterize speed of treatment onset. Safety, tolerability and plasma pharmacokinetic data will also be evaluated.

"Completing enrollment in our Phase IIb trial with tezampanel is an i
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 This report analyzes the ... the following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, and ... the US Canada, Japan , ... Latin America , and Rest of World. Annual estimates ... Also, a six-year historic analysis is provided for these markets. ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
(Date:10/1/2014)... Engineering and Physical Sciences Research Council (EPSRC) will ... industrial control systems which run, for example, manufacturing ... rail network. , The research will help ... infiltrating the systems behind our critical national infrastructure. ... Control Systems (RITICS), based at Imperial College London, ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... The U.S. Food and Drug Administration (FDA) has decided ... (R) (infliximab) to be used in the treatment of ... today. Crohn's disease affects the gastrointestinal tract and causes ... now there is no drug to treat children who ...
... Illinois at Chicago in collaboration with their colleagues from ... enzyme in the virus that causes SARS//, severe acute ... in the March 27 issue of the Proceedings of ... form a new drug target for drug makers. ...
... the cause of four men whose lives took a turn ... German company// TeGenero and medical research company Parexel, has received ... handling the case, has felt ignored after receiving no response ... conducted at Northwick Park Hospital in Harrow, north-west London, last ...
... It is already known to us that some popular spices ... Liu, an assistant professor of obstetrics// and gynecology at the ... powder dissolved in solution by putting it on ovarian cancer ... that ginger can kill ovarian cancer cells. But the study ...
... Harris Interactive? for the Vagisil Women's Health CenterSM conducted a ... of today's American women are taking active roles in their ... thirds of women aged 18 and older (63 percent) report ... go to a gynecologist, 61 percent say they "always" go ...
... the risk of coronary heart attack and could in general be ... study of 4,400 men and women aged 65 and over by ... a link between the amount of alcohol drunk and the likelihood ... ,People who drink 14 or more glasses of wine or ...
Cached Medicine News:Health News:FDA Accords Priority Review For Pediatric Crohn's Disease Drug 2Health News:Spices Could Be Employed To Treat Certain Cancers 2Health News:Women aware of “feminine health” : their attitud 2
Multi piece lens, AC depth: 4.2....
Liberty Three Piece PMMA Lens with UV Absorber....
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... patients to focus seamlessly near, ... way the eyes natural lens ... to a remarkable new level. ... patients vision to the way ...
Medicine Products: